Myovant Sciences Ltd (MYOV)

NYSE
15.31
-1.50(-8.92%)
After Hours
15.31
0.00(0.00%)
- Real-time Data
  • Volume:
    1,387,349
  • Bid/Ask:
    15.30/15.31
  • Day's Range:
    15.30 - 17.26

MYOV Overview

Prev. Close
16.81
Day's Range
15.3-17.26
Revenue
144.95M
Open
17.16
52 wk Range
15.31-30.76
EPS
-2.62
Volume
1,387,349
Market Cap
1.43B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
591,637
P/E Ratio
-
Beta
2.77
1-Year Change
-36.81%
Shares Outstanding
93,309,055
Next Earnings Date
Feb 15, 2022
What is your sentiment on Myovant Sciences Ltd?
or
Market is currently closed. Voting is open during market hours.

Myovant Sciences Ltd Company Profile

Employees
407

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women’s health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellSellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell
  • $40-45 buyout target by Sumitovant in 2-4 weeks
    0
    • stock will be supported higher on next financial report I believe...
      0
      • FDA APPROVED vaccines for COVID-19. Stocks dropped
        0
        • FDA approval for Orgovyx in prostate cancer!
          0
          • FDA approval for Orgovyx in prostate cancer!
            0
            • FDA approval for Orgovyx in prostate cancer
              0
              • Here we go
                0
                • It will go up soon
                  0
                  • ANY advise please for MYOVANT ? is going to rise up soon or in long term please ? best regards, Szilike.
                    0
                    • one of the best stocks you can get right now..hurry and jump in
                      0
                  • Dilutive share issue may be coming.
                    1
                    • if look to left...article saying myov to receive asddl financeing from sumitomo dain...200m low interest 5 year loan.....then again they still may do an offering
                      0
                  • start button pressed.eject.
                    0
                    • entry point today.thanks to donald duck.
                      0
                      • great news are coming with Santa.fearless buy and stay tuned.
                        0
                        • get ready.30$ coming soon
                          0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.